| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/19/2001 | CA2385784A1 Antimicrobial compositions comprising multidrug efflux pumps |
| 04/19/2001 | CA2383650A1 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
| 04/19/2001 | CA2382737A1 Suppressor cells for prevention and treatment of immune responses in transplantation |
| 04/19/2001 | CA2382727A1 Methods of enhancing chemotherapy with the use of an imidazole |
| 04/19/2001 | CA2289365A1 Methods and compositions for predicting, diagnosing and treating lipodystrophy |
| 04/18/2001 | EP1092770A2 Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same |
| 04/18/2001 | EP1092727A2 G-protein receptor |
| 04/18/2001 | EP1092437A1 The use of epidermal growth factor as a gastrointestinal therapeutic agent |
| 04/18/2001 | EP1092433A2 Compositions and methods for treating or preventing inflammatory diseases |
| 04/18/2001 | EP1092431A2 Lasofoxifene compositions |
| 04/18/2001 | EP1092040A2 METHODS OF INHIBITING $i(HELICOBACTER PYLORI) |
| 04/18/2001 | EP1092032A2 Human oxidoreductase proteins |
| 04/18/2001 | EP1092025A1 Human emr1-like g protein coupled receptor |
| 04/18/2001 | EP1092023A2 Molecules associated with apoptosis |
| 04/18/2001 | EP1092019A1 Human homologue of unc-53 protein of c. elegans |
| 04/18/2001 | EP1092018A1 Kv6.2, A VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT |
| 04/18/2001 | EP1091974A2 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same |
| 04/18/2001 | EP1091759A2 Composition for the induction of apoptosis in target cells |
| 04/18/2001 | EP1091755A1 Particulate delivery systems and methods of use |
| 04/18/2001 | EP1091752A1 Compositions comprising endotoxin neutralizing protein and derivatives and uses thereof |
| 04/18/2001 | EP1091745A1 Treatment of hyperproliferative disorders |
| 04/18/2001 | EP1091739A1 Method for inhibiting c-jun expression using jak-3 inhibitors |
| 04/18/2001 | EP1091735A1 Application for utility patent for improved enriched platelet wound healant |
| 04/18/2001 | EP0935462A4 Photopheresis treatment of leukocytes |
| 04/18/2001 | EP0546160B1 Method of reversing local anesthesia and reagent system therefor |
| 04/18/2001 | CN1291896A Pharmaceutical compositions for ulcer |
| 04/18/2001 | CN1291893A Use of D1/D5 antagonist for treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating desorders, impulse control disorders and autism |
| 04/18/2001 | CN1291890A 20-Hete antagonists and agonists |
| 04/18/2001 | CN1291589A Electrolytic reduction water and anti-cancer medicine and preparation method and equipment thereof |
| 04/17/2001 | US6218528 MurB |
| 04/17/2001 | US6218526 Polynucleotide encoding human netrin-1 |
| 04/17/2001 | US6218506 Soluble brain protein for the detection, prevention and treatment of alzhiemer's disease |
| 04/17/2001 | US6218435 Reduction of hair growth |
| 04/17/2001 | US6218428 Ophthalmic composition |
| 04/17/2001 | US6218424 Heterocyclic ketone and thioester compounds and uses |
| 04/17/2001 | US6218423 Administering pyrrolidine derivative for therapy of nerve-related vision disorder, improving vision, treating memory impairment, or enhancing memory performance in animal |
| 04/17/2001 | US6218418 Therapy of cell proliferative disorders associated with an altered cell dependent kinase activity by administering amino pyrazole derivative to mammal |
| 04/17/2001 | US6218414 Administering an effective amount of an angiotensin ii antagonist and a benzofuran derivative with antiarrhythmic activity for therapy of cardiovascular complaints |
| 04/17/2001 | US6218410 Medicines comprising Rho kinase inhibitor |
| 04/17/2001 | US6218409 Administering insulin sensitivity enhancer in combination with an aldose reductase inhibitor for reducing side effects of diabetic drugs |
| 04/17/2001 | US6218403 Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an HMG-CoA-reductase inhibitor |
| 04/17/2001 | US6218395 For relieving psychic and somatic symptoms of anxiety disorder or adjustment disorder |
| 04/17/2001 | US6218390 Morpholinone and morpholine derivatives and uses thereof |
| 04/17/2001 | US6218383 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| 04/17/2001 | US6218381 Fused imidazole derivatives as multidrug resistance modulators |
| 04/17/2001 | US6218377 Methods for the administration of amifostine and related compounds |
| 04/17/2001 | US6218359 Treating autoimmune, arthritic, tumor diseases |
| 04/17/2001 | US6218159 Amino acid sequence; bacteriostats; bactericides; antibiotics; diagnosis of infections; drug screening |
| 04/17/2001 | US6218136 Methods of the identification of pharmaceutically active compounds |
| 04/17/2001 | US6218133 Materials and methods for detection and treatment of immune system dysfunctions |
| 04/17/2001 | US6218132 Activating t-cells with antigen to cause expansion, reactivating with antigen and antigen presenting cells to induce secretion of soluble factor, then detecting by capturing factor on solid support |
| 04/17/2001 | US6217904 Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant |
| 04/17/2001 | US6217900 Vesicular complexes and methods of making and using the same |
| 04/17/2001 | US6217889 Personal care articles |
| 04/17/2001 | US6217885 Skin disorders; therapy for insect bites |
| 04/17/2001 | US6217866 Antitumor agents mixture |
| 04/17/2001 | US6217861 pneumococcus; use as drug target for drug screening antibiotics |
| 04/17/2001 | CA2163107C Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates |
| 04/17/2001 | CA2157003C Hormone replacement therapy |
| 04/17/2001 | CA2055493C Antineoplastic solution and method for treating neoplasms |
| 04/12/2001 | WO2001025793A2 Diagnosis of coeliac disease using a gliadin epitope |
| 04/12/2001 | WO2001025486A1 Methods for identifying rna binding compounds |
| 04/12/2001 | WO2001025446A1 Dna encoding prost 07 polypeptide |
| 04/12/2001 | WO2001025442A1 Dna polymerase lambda and uses thereof |
| 04/12/2001 | WO2001025437A2 Growth factor polypeptides and nucleic acids encoding same |
| 04/12/2001 | WO2001025433A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 04/12/2001 | WO2001025423A1 Splice variant of head trauma induced cytoplasmatic calcium binding protein |
| 04/12/2001 | WO2001025414A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 04/12/2001 | WO2001025410A2 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 04/12/2001 | WO2001025408A1 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 04/12/2001 | WO2001025397A2 Compositions and methods for tumor-targeted delivery of effector molecules |
| 04/12/2001 | WO2001025390A2 Water unstable foam compositions |
| 04/12/2001 | WO2001025271A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | WO2001025269A2 Human g-protein coupled receptor |
| 04/12/2001 | WO2001025258A1 Human inwardly rectifying potassium channel subunit |
| 04/12/2001 | WO2001025226A1 Dithiolane derivatives |
| 04/12/2001 | WO2001025220A1 Triazine kinase inhibitors |
| 04/12/2001 | WO2001025208A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 04/12/2001 | WO2001025200A1 Cyclic amine compounds as ccr5 antagonists |
| 04/12/2001 | WO2001025188A1 Novel carbamates and ureas |
| 04/12/2001 | WO2001024828A2 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 04/12/2001 | WO2001024827A2 INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 04/12/2001 | WO2001024826A2 Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens |
| 04/12/2001 | WO2001024823A1 Cd40 antagonist for treating psoriasis |
| 04/12/2001 | WO2001024817A2 Pharmaceutical compositions of fibrinolytic agent |
| 04/12/2001 | WO2001024815A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 04/12/2001 | WO2001024814A1 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 04/12/2001 | WO2001024807A2 Method for calming human beings using personal care compositions |
| 04/12/2001 | WO2001024801A1 Pharmaceutical formulations containing poorly soluble drug substances |
| 04/12/2001 | WO2001024799A1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 04/12/2001 | WO2001024797A1 Integrin receptor antagonists |
| 04/12/2001 | WO2001024795A1 RETARD FORM CONTAINING α-LIPOIC ACID (DERIVATIVES) |
| 04/12/2001 | WO2001024792A1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 04/12/2001 | WO2001024791A1 Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders |
| 04/12/2001 | WO2001024788A2 Treating endometriosis or infertility, or improving fertility |
| 04/12/2001 | WO2001024785A2 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 04/12/2001 | WO2001024784A2 New use |
| 04/12/2001 | WO2001024781A2 Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| 04/12/2001 | WO2001024778A1 Anti-inflammatory pharmaceutical formulations |
| 04/12/2001 | WO2001024774A1 Ortho ester lipids |